CELZ / Creative Medical Technology Holdings, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 Creative Medi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 Creative Med

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 3 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 3 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500

PROSPECTUS 1,799,774 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-286346 PROSPECTUS 1,799,774 Shares of Common Stock This prospectus relates to the possible resale from time to time of up to an aggregate of 1,799,774 shares of our common stock, par value $0.001 per share, issuable upon the exercise of common stock purchase warrants (the “Warrants”) issued in a private placement on March 6, 2025 to the selling

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporati

April 9, 2025

April 9, 2025 Via Edgar Mr. Tyler Howes Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-3 Filed April 2, 2025 File No. 333-286346 Request for Acceleration Dear Mr. Howes: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Creative Me

Clawback Policy of Creative Medical Technology Holdings, Inc.

EXHIBIT 97.1 CLAWBACK POLICY This Clawback Policy (this “Policy”) was approved on April 4, 2025, with retroactive effect to December 1, 2023 (the “Effective Date”) by the Compensation Committee of the Board of Directors (the “Board”) of Creative Medical Technology Holdings, Inc. (the “Company”). This Policy is adopted pursuant to and intended to comply with Rule 5608 (Recovery of Erroneously Award

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500

As filed with the Securities and Exchange Commission on April 2, 2025

As filed with the Securities and Exchange Commission on April 2, 2025 Registration No.

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Creative Medical Technology Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

Exhibit 4.4

EXHIBIT 4.4 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of shares of capital stock of Creative Medical Technology Holdings, Inc. (the “Company,” “we,” “us,” or “our”). The brief description is based upon our Articles of Incorporation (as amended, our “Articles of Incorporation”), our Bylaw

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

LIST OF SUBSIDIARIES OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

EXHIBIT 21.1 LIST OF SUBSIDIARIES OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AlloCelz LLC, a Nevada limited liability company BioDefense Inc., a Nevada corporation Creative Medical Technologies, Inc., a Nevada corporation ImmCelz Inc., a Nevada corporation StemSpine, Inc., a Nevada corporation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporati

Form of Inducement Warrant

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Inducement Letter

EXHIBIT 10.1 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. March 6, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Creative Medical Technology Holdings, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants to purchase shares of the Company’s common st

Certificate of Certificate of Withdrawal of Certificate of Designation of Series B Preferred Stock, as filed with the Secretary of State of the State of Nevada on December 20, 2024

EXHIBIT 3.3

Certificate of Certificate of Withdrawal of Certificate of Designation of Series A Preferred Stock, as filed with the Secretary of State of the State of Nevada on December 20, 2024

EXHIBIT 3.2

Certificate of Amendment to Articles of Incorporation Pursuant to NRS 78.385 and 78.390, as filed with the Secretary of State of the State of Nevada on December 19, 2024 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 26, 2024).

EXHIBIT 3.1

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

837,104 Shares of Common Stock

PROSPECTUS 837,104 Shares of Common Stock This prospectus relates to the possible resale from time to time of up to an aggregate of 837,104 shares of our common stock, par value $0.

November 15, 2024

November 15, 2024 Via Edgar Mr. Joshua Gorsky Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-1 Filed November 8, 2024 File No. 333-283091 Request for Acceleration Dear Mr. Gorsky: Pursuant to Rule 461 under the Securities Act of 1933, as amended, C

As filed with the Securities and Exchange Commission on November 8, 2024

As filed with the Securities and Exchange Commission on November 8, 2024 Registration No.

Subsidiaries **

EXHIBIT 21.1 SUBSIDIARIES OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Creative Medical Technologies, Inc., a Nevada corporation StemSpine, Inc., a Nevada corporation ImmCelz Inc., a Nevada corporation AlloCelz LLC, a Nevada limited liability company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Filing Fee Table**

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Creative Medical Technology Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(

Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

EXHIBIT 99.1 Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PHOENIX, October 23, 2024- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(

418,552 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-282512 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 15, 2024) 418,552 Shares of Common Stock We are offering 418,552 shares of our common stock, par value $0.001 per share, directly to certain investors pursuant to this prospectus supplement and the accompanying prospectus. Each share of common stock is being sold at a price of $4.42. In

(incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 23, 2024)

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 22, 2024, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the t

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of October 22, 2024 between Creative Medical Technology Holdings, Inc. and the purchasers named therein (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 23, 2024).

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpor

Form of Placement Agent Warrant

EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

(incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 23, 2024)

EXHIBIT 10.2 PLACEMENT AGENCY AGREEMENT October 22, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $1,849,999.84 of securities of th

Creative Medical Technology Holdings, Inc. 211 E Osborn Road Phoenix, Arizona 85012 October 10, 2024

Creative Medical Technology Holdings, Inc. 211 E Osborn Road Phoenix, Arizona 85012 October 10, 2024 Via Edgar Ms. Doris Stacey Gama Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-3 Filed October 4, 2024 File No. 333-282512 Request for Acceleration

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

As filed with the Securities and Exchange Commission on October 4, 2024

As filed with the Securities and Exchange Commission on October 4, 2024 Registration Statement No.

Filing Fee Table**

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Creative Medical Technology Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commission Fil

Certificate of Designation of the Series B Preferred Stock

EX-3.1 2 celzex31.htm CERTIFICATE OF DESIGNATION EXHIBIT 3.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICA

Exhibit 4.4

EXHIBIT 4.5 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of shares of capital stock of Creative Medical Technology Holdings, Inc. (the “Company,” “we,” “us,” or “our”). The brief description is based upon our Articles of Incorporation (as amended, our “Articles of Incorporation”), our Bylaw

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

EX-10.8

EXHIBIT 10.8

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDI

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

EXHIBIT 99.1 Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements Phoenix, AZ - June 28, 2023 - Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that on June 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):June 27, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):June 27, 2023 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction Identification

Certificate of Change Pursuant to NRS 78.209, as filed with the Secretary of State of the State of Nevada on June 1, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2023).

EXHIBIT 3.1 FRANCISCO V. AGUILAR Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 TYPE OR PRINT - USE DARK INK ONLY - DO NOT HIGHLIGHT INSTRUCTIONS: 1. Enter the current name as on file with the Nevada Secretary of State and enter the Entity or Nevada Business Identification Number (NVID). 2

Creative Medical Technology Holdings Announces Reverse Stock Split

EXHIBIT 99.1 Creative Medical Technology Holdings Announces Reverse Stock Split Phoenix, AZ - June 9, 2023 - Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the company’s Board of Directors

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporatio

CELZ / Creative Medical Technology Holdings Inc / Markey John - MARKEY JOHN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Name of Issuer) COM NEW (Title of Class of Securities) 22529Y309 (CUSIP Number) May 25, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MED

CELZ / Creative Medical Technology Holdings Inc / Markey John - MARKEY JOHN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Name of Issuer) COM NEW (Title of Class of Securities) 22529Y309 (CUSIP Number) April 28, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICA

Research Tools Purchase Agreement, dated December 15, 2022, between Creative Medical Technology Holdings, Inc and Narkeshyo LLC (incorporated by reference to Exhibit 10.9 of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2023)

EXHIBIT 10.9

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

Description of Registrant’s Securities*

EXHIBIT 4.5 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of shares of capital stock of Creative Medical Technology Holdings, Inc. (the “Company,” “we,” “us,” or “our”). The brief description is based upon our Articles of Incorporation (as amended, our “Articles of Incorporation”), our Bylaw

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporatio

PROSPECTUS 22,666,668 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-264824 PROSPECTUS 22,666,668 Shares of Common Stock This prospectus relates to the possible resale from time to time of up to 22,666,668 shares of our common stock, par value $0.001 per share, which are held by, or may be issued to, the selling stockholders identified in this prospectus. We will not receive any proceeds from the sale of any sha

Creative Medical Technology Holdings, Inc. 211 E. Osborn Road Phoenix, Arizona 85012 May 17, 2022

CORRESP 1 filename1.htm Creative Medical Technology Holdings, Inc. 211 E. Osborn Road Phoenix, Arizona 85012 May 17, 2022 Via Edgar Ms. Christine Westbrook Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-3 Filed May 10, 2022 File No. 333-264824 Dear Ms. We

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Creative Medical Technology Holdings, Inc.

As filed with the Securities and Exchange Commission on May 10, 2022

As filed with the Securities and Exchange Commission on May 10, 2022 Registration No.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Securities Purchase Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the te

Securities Purchase Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the te

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Registration Rights Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the S

Creative Medical Technology Holdings, Inc. 211 E. Osborn Road Phoenix, Arizona 85012 May 4, 2022

Creative Medical Technology Holdings, Inc. 211 E. Osborn Road Phoenix, Arizona 85012 May 4, 2022 Via Edgar Mr. Daniel Crawford Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Request for Withdrawal of Registration Statement on Form S-1 Filed April 22, 2022 File No. 333-264455 Dear Ms. Cra

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Registration Rights Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the S

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Pre-Funded Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Pre-Funded Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of April 29, 2022 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICA

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Creative Medical Technology Holdings, Inc.

As filed with the Securities and Exchange Commission on April 22, 2022

As filed with the Securities and Exchange Commission on April 22, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

CELZ / Creative Medical Technology Holdings Inc / Altium Capital Management LP - AMENDMENT TO SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Creative Medical Technology Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 22529Y309 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate

CELZ / Creative Medical Technology Holdings Inc / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 22529Y309 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Creative Medical Technology Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 22

EXHIBIT 1

Creative Medical Technology Holdings, Inc. SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi

CELZ / Creative Medical Technology Holdings Inc / L1 Capital Global Opportunities Master Fund, Ltd. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 Creative Medical Technology Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 22529Y309 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

Employment Agreement between Creative Medical Technology Holdings, Inc. Company and Donald Dickerson, dated as of February 9, 2022. (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2022).

EXHIBIT 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of February 9, 2022, (the ?Effective Date?) by and between CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., a Nevada corporation with its principal place of business at 211 E Osborn Road, Phoenix, AZ 85012 (the ?Company?) and DONALD DICKERSON, an individual residing at 822 Vera Street, San Diego, CA 92075 (?Executive?).

Employment Agreement between Creative Medical Technology Holdings, Inc. and Timothy Warbington, dated as of February 9, 2022. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2022).

EXHIBIT 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of February 9, 2022, (the ?Effective Date?) by and between CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., a Nevada corporation with its principal place of business at 211 E Osborn Road, Phoenix, AZ 85012 (the ?Company?) and TIMOTHY WARBINGTON, an individual residing at 3008 W. Lupine Ave. Phoenix. AZ 85029 (?Executive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commission

CELZ / Creative Medical Technology Holdings Inc / Altium Capital Management LP - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

SC 13G 1 celz-sc13g120321.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Creative Medical Technology Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 22529Y309 (CUSIP Number) Decembe

EXHIBIT 1:

Altium Capital Management, LP SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.

CELZ / Creative Medical Technology Holdings Inc / CVI Investments, Inc. - SC 13G Passive Investment

CUSIP No: 22529Y309 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* Creative Medical Technology Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 225

CELZ / Creative Medical Technology Holdings Inc / L1 Capital Global Opportunities Master Fund, Ltd. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Creative Medical Technology Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 22529Y309 (CUSIP Number) December 7, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

Warrant Agency Agreement between Creative Medical Technology Holdings, Inc. and vStock Transfer LLC dated December 7, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2021).

EXHIBIT 10.1 Creative Medical Technology Holdings, Inc. and VStock Transfer, LLC as Warrant Agent Warrant Agency Agreement Dated as of December 7, 2021 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of December 7, 2021 (?Agreement?), by and between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and VStock Transfer LLC, a California limited liability

Underwriter’s Warrant issued to Roth Capital Partners, LLC dated December 7, 2021 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2021).

EXHIBIT 4.1 REPRESENTATIVE COMMON STOCK PURCHASE WARRANT CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Warrant Shares: 348,750 Initial Exercise Date: December 7, 2021 THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Roth Capital Partners, LLC or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commission

Underwriting Agreement, dated December 3, 2021, by and between Creative Medical Technology Holdings, Inc. and Roth Capital Partners, LLC

EXHIBIT 1.1 3,875,000 SHARES OF COMMON STOCK AND 3,875,000 COMMON WARRANTS OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT December 3, 2021 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: The undersigned

Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market

EXHIBIT 99.1 Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market Phoenix, AZ, December 3, 2021 ? Creative Medical Technology Holdings, Inc. (the ?Company") (NASDAQ:CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced the pricing of

PROSPECTUS 3,875,000 Shares of Common Stock Warrants to Purchase up to 3,875,000 Shares of Common Stock

Filed Pursuant to Rule 424(b)(4) Registration File No. 333-259834 PROSPECTUS 3,875,000 Shares of Common Stock Warrants to Purchase up to 3,875,000 Shares of Common Stock This is a firm commitment public offering of 3,875,000 shares of our common stock and warrants to purchase up to 3,875,000 shares of our common stock (which we refer to as ?Public Warrants?) at a combined public offering price of

101 Park Avenue

CORRESP 1 filename1.htm 101 Park Avenue Suite 1700 New York, NY 10178 Tel (212) 878-7900 Fax (212) 692-0940 www.foxrothschild.com December 2, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Christine Westbrook Celeste Murphy Re: Creative Medical Technology Holdings, Inc. Amendment No. 2 to Regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 87-0622284 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer

As filed with the Securities and Exchange Commission on December 2, 2021

As filed with the Securities and Exchange Commission on December 2, 2021 Registration No.

Form of Underwriting Agreement

EXHIBIT 1.1 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS AND COMMON WARRANTS OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT , 2021 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: The undersigned, Creative

As filed with the Securities and Exchange Commission on December 1, 2021

As filed with the Securities and Exchange Commission on December 1, 2021 Registration No.

Form of pre-funded warrant

EXHIBIT 4.4 EXHIBIT F PRE-FUNDED COMMON STOCK PURCHASE WARRANT CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any

Creative Medical Technology Holdings, Inc. 211 E. Osborn Road Phoenix, Arizona 85012 November 30, 2021

Creative Medical Technology Holdings, Inc. 211 E. Osborn Road Phoenix, Arizona 85012 November 30, 2021 Via Edgar Ms. Christine Westbrook Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-1 Filed November 23, 2021 File No. 333-259834 Dear Ms. Westbrook: Pursu

Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660

CORRESP 1 filename1.htm Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 November 30, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-259834) Ladies and Gentlemen: In connection with the above-captioned registration statement, an

Form of Public Warrant issued in December 7, 2021 public offering (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 23, 2021).

EXHIBIT 4.1 EXHIBIT E COMMON STOCK PURCHASE WARRANT CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d

Form of Warrant Agency Agreement

EXHIBIT 4.2 Creative Medical Technology Holdings, Inc. and VStock Transfer, LLC as Warrant Agent Warrant Agency Agreement Dated as of , 2021 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2021 (?Agreement?), by and between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and VStock Transfer LLC, a California limited liability company (?VStock? o

Form of Representative Warrant

EXHIBIT 3.3 EXHIBIT E REPRESENTATIVE COMMON STOCK PURCHASE WARRANT CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth,

As filed with the Securities and Exchange Commission on November 23, 2021

As filed with the Securities and Exchange Commission on November 23, 2021 Registration No.

Form of Underwriting Agreement

EXHIBIT 1.1 SHARES OF COMMON STOCK AND WARRANTS OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT , 2021 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: The undersigned, Creative Medical Technology Holding

101 Park Avenue

101 Park Avenue Suite 1700 New York, NY 10178 Tel (212) 878-7900 Fax (212) 692-0940 www.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREA

Certificate of Change Pursuant to NRS 78.209, as filed with the Secretary of State of the State of Nevada on November 8, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2021).

EXHIBIT 3.1

Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market

EXHIBIT 99.1 Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market November 9, 2021 Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings, Inc. (the ?Company?), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpor

Certificate of Amendment to Articles of Incorporation Pursuant to NRS 78.385 and 78.390, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).

EXHIBIT 3.1

Certificate of Withdrawal of Certificate of Designation of Series C Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).

EXHIBIT 3.3

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction of incorpor

Certificate of Withdrawal of Certificate of Designation of Series B Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).

EXHIBIT 3.2

Consent of Susan Snow to be named as a director

EXHIBIT 99.2 CONSENT TO BE NAMED AS A PROSPECTIVE DIRECTOR As required by Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference to my name as a prospective director of Creative Medical Technology Holdings, Inc. (the ?Registrant?) in the prospectus forming a part of a registration statement on Form S-1 to be filed by the Registrant with the U.S. Securities and Exc

Consent of Michael Finger to be named as a director

EXHIBIT 99.1 CONSENT TO BE NAMED AS A PROSPECTIVE DIRECTOR As required by Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference to my name as a prospective director of Creative Medical Technology Holdings, Inc. (the ?Registrant?) in the prospectus forming a part of a registration statement on Form S-1 to be filed by the Registrant with the U.S. Securities and Exc

Consent of Bruce Urdang to be named as a director

EXHIBIT 99.3 CONSENT TO BE NAMED AS A PROSPECTIVE DIRECTOR As required by Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference to my name as a prospective director of Creative Medical Technology Holdings, Inc. (the ?Registrant?) in the prospectus forming a part of a registration statement on Form S-1 to be filed by the Registrant with the U.S. Securities and Exc

Agreement dated December 28, 2020, between Jadi Cell LLC and ImmCelz, Inc. (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 28, 2021).

EXHIBIT 10.4 AGREEMENT This Agreement (?Agreement?), dated as of December 28, 2020 (the ?Effective Date?), is entered into by and between Jadi Cell LLC, a Delaware limited liability company, with offices located at 1100 Biscayne Blvd., #6104, Miami, Florida 33132 (?Licensor?), and ImmCelz Inc. the successor identity of BioStem Acquisitions Inc, a Nevada corporation, a subsidiary of Creative Medica

As filed with the Securities and Exchange Commission on September 28, 2021

As filed with the Securities and Exchange Commission on September 28, 2021 Registration No.

2021 Equity Incentive Plan (incorporated by reference to Appendix B to the Company’s Information Statement on Schedule 14C filed with the Securities and Exchange Commission on September 24, 2021).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) ? Definitive Information Statement CREATIVE MEDICAL TE

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) ? Definitive Information Statement CREATIVE MEDICAL TE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Securities Purchase Agreement dated as of August 9, 2021 between Creative Medical Technology Holdings, Inc. and the purchasers named therein

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 9, 2021, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the te

Form of 15% Original Issue Discount Senior Note Due February 11, 2022 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2021).

EXHIBIT 4.1 Original Issue Date: August 11, 2021 $ ORIGINAL ISSUE DISCOUNT SENIOR NOTE DUE FEBRUARY 11, 2022 THIS ORIGINAL ISSUE DISCOUNT SENIOR NOTE is one of a series of duly authorized and validly issued Original Issue Senior Notes of Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), having its principal place of business at 3008 W Lupine Avenue, Phoenix, AZ 8502

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of August 9, 2021 between Creative Medical Technology Holdings, Inc. and the purchasers named therein (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2021).

EX-4.2 3 celzex42.htm COMMON STOCK PURCHASE WARRANT EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Certificate of Designation of the Series C Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2021).

EXHIBIT 3.1 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK The undersigned, Timothy Warbington, does hereby certify that: 1. He is the Chief Executive Officer, of Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Corporation? or the ?Company?). 2. The Corporation is authorized

Securities Purchase Agreement, dated as of March 30, 2021, between Creative Medical Technology Holdings, Inc. and Fourth Man, LLC

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 30, 2021, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and Fourth Man, LLC (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amen

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine

EXHIBIT 99.1 Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine March 23, 2021 Phoenix, AZ, – Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to lau

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Articles of Incorporation of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).

EXHIBIT 3.1 ARTICLES OF INCORPORATION (As Filed on 12/3/1998, As Amended on 9/05/2007, 7/16/2008, 7/11/2011, 5/18/2016, & 2/13/18) Creative Medical Technology Holdings, Inc. ARTICLE I (As amended 5/18/2016) The name of the corporation (which is hereinafter referred to as the "Corporation") is Creative Medical Technology Holdings, Inc. ARTICLE II The address of the registered office of the Corporat

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

Amendment and Waiver to Patent Purchase Agreement dated November 14, 2017, between Creative Medical Technology Holdings, Inc. and Creative Medical Health, Inc. (incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).

EXHIBIT 10.29

Code of Business Conduct and Ethics

EXHIBIT 10.28 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction This Code of Business Conduct and Ethics (this ? Code ?) has been adopted by our board of directors (the ? Board of Directors ?) to summarize the standards of business conduct that must guide our actions. This Code applies to all directors, officers, and employees of Creative Medical Techno

Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).

EXHIBIT 21.1 SUBSIDIARIES OF CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Name Ownership State of Incorporation StemSpine Inc. 100.00% Nevada ImmCelz Inc. 100.00% Nevada Creative Medical Technologies Inc. 100.00% Nevada AmnioStem LLC 100.00% Nevada

Certificate of Amendment to Certificate of Designation of the Series A Preferred Stock Pursuant to NRS 78.1955, filed with the Secretary of State of the State of Nevada on March 11, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).

EXHIBIT 3.1 1 2

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction of incorporat

Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites

EXHIBIT 99.1 Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites March 10, 2021 Phoenix, AZ, – Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has started recruitment of clinical sites for St

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy Commercial Stage Regenerative Medicine Company Expands it’s Hold “Rea

EXHIBIT 99.2 Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine? Personalized Adult Stem Cell Therapy Commercial Stage Regenerative Medicine Company Expands it?s Hold ?Ready to Commercialize? Autologous Bone Marrow Procedures March 4, 2021 Phoenix, AZ (OTC - CELZ) Creative Medical Technology Holdings announ

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commission Fi

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

EXHIBIT 99.1 Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application March 3, 2021 – Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA’s submission requirements, the Company’s ImmCelz® Investigational New Drug Application (IND) for the treatment of Stroke will be resubmitted to the FDA in elec

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incor

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz® Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation

EXHIBIT 99.1 Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz® Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation February 16, 2021 Phoenix, AZ (OTC – CELZ) Creative Medical Technology Holdings announced today filing of a patent application covering the use of ImmCelz® rege

Certificate of Designation of the Series B Preferred Stock of Creative Medical Technology Holdings, Inc., filed February 11, 2021

EX-3.1 2 celzex31.htm CERTIFICATE OF DESIGNATION EXHIBIT 3.1 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK The undersigned, Timothy Warbington, does hereby certify that: 1. He is the Chief Executive Officer, of Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Corporation” or

Securities Purchase Agreement, dated as of February 11, 2021, between Creative Medical Technology Holdings, Inc. and BHP Capital NY, Inc.

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 11, 2021, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the ?Company?), and BHP Capital NY, Inc. (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz® Regenerative Immunotherapy

EX-99.1 2 celzex991.htm PRESS RELEASE EXHIBIT 99.1 Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz® Regenerative Immunotherapy February 8, 2021 Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today rec

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem® Female Infertility/Ovarian Failure Treatment Company Advances Towards Clinical Trial to Address Premature Ovarian Failure Patients

EXHIBIT 99.2 Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem? Female Infertility/Ovarian Failure Treatment Company Advances Towards Clinical Trial to Address Premature Ovarian Failure Patients February 10, 2021 Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem? female i

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpor

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz® Induces Surge of Therapeuti

EXHIBIT 99.1 Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz® Induces Surge of Therapeutic Protein HGF-1 February 1, 2021 - Phoenix, AZ (OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstra

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpor

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commission

Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy Company to Start Clinical Trial to Address 30 Billion Dollar Stroke Market Using Novel Ce

EXHIBIT 99.1 Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy Company to Start Clinical Trial to Address 30 Billion Dollar Stroke Market Using Novel Cell Therapy Phoenix AZ – January 12, 2021 (OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigatio

Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem Cell Types

EX-99.1 2 celzex991.htm PRESS RELEASE EXHIBIT 99.1 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem Cell Types December 22, 2020 – Phoenix, AZ Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today data identifyin

Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model Company Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using “Reprogrammed” Immune C

EXHIBIT 99.2 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model Company Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using “Reprogrammed” Immune Cells December 29, 2020 – Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction (Commissio

Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz® Regenerative Immunotherapy Clinical Stage Stem Cell Company Expands its Cellular Therapy Platforms

EXHIBIT 99.3 Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz® Regenerative Immunotherapy Clinical Stage Stem Cell Company Expands its Cellular Therapy Platforms December 31, 2020 – Phoenix, AZ (OTC – CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREA

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Code of Business Conduct and Ethics

Exhibit 10.28 Creative Medical Technology Holdings, Inc. CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction This Code of Business Conduct and Ethics (this “Code”) has been adopted by our board of directors (the “ Board of Directors ”) to summarize the standards of business conduct that must guide our actions. This Code applies to all directors, officers, and employees of Creative Medical Technolo

Articles of Incorporation

Exhibit 3.1 ARTICLES OF INCORPORATION (As Filed on 12/3/1998, As Amended on 9/05/2007, 7/16/2008, 7/11/2011, 5/18/2016, & 2/13/18) Creative Medical Technology Holdings, Inc. ARTICLE I (As amended 5/18/2016) The name of the corporation (which is hereinafter referred to as the "Corporation") is Creative Medical Technology Holdings, Inc. ARTICLE II The address of the registered office of the Corporat

CELZ / Creative Medical Technology Holdings, Inc. 10-K - Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the terms of the common stock of Creative Medical Technology Holdings, Inc. is not complete and is qualified in its entirety by reference to our Articles of Incorporation, as amended, and our Bylaws. General Our curre

CELZ / Creative Medical Technology Holdings, Inc. NT 10-K - - NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-53500 CUSIP NUMBER 22529Y 200 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2019 o

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commission F

Certificate of Amendment to Certificate of Designation Pursuant to NRS 78.1955, filed with the Secretary of State of the State of Nevada on March 19, 2020.

Exhibit 3.1

Certificate of Amendment Pursuant to NRS 78.385 and 78.390, as filed with the Secretary of State of the State of Nevada on January 28, 2020

Exhibit 3.1 Certificate of Amendment To Articles Of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock) 1. Name of Corporation: Creative Medical Technology Holdings, Inc. 2. The Articles have been amended as follows: Upon the filing of this Certificate Amendment, the outstanding shares of common stock of the Corporation, par value $.001 per sh

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2020 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commission

JLLM / Jolley Marketing, Inc. DEFR14C - - DEFR14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1) Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) x Definitive Information Statement

JLLM / Jolley Marketing, Inc. DEF 14C - - DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) x Definitive Information Statement CREATIVE MEDICAL TE

JLLM / Jolley Marketing, Inc. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREA

JLLM / Jolley Marketing, Inc. PRE 14C - - PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) ¨ Definitive Information Statement CREATIVE MEDICAL TE

Securities Purchase Agreement, dated as of October 11, 2019, between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 11, 2019, among Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, the parties heret

Form of 8% Original Issue Discount Senior Convertible Note issued under Securities Purchase Agreement dated as of October 11, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commission

JLLM / Jolley Marketing, Inc. DEF 14C - - DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) x Definitive Information Statement CREATIVE MEDICAL TE

Creative Medical Technology Holdings Reports completion and submission of Clinical Trial Data on CaverStem® Procedure for Drug Resistant Erectile Dysfunction Patients Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone

Exhibit 99.1 Creative Medical Technology Holdings Reports completion and submission of Clinical Trial Data on CaverStem® Procedure for Drug Resistant Erectile Dysfunction Patients Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone Marrow Concentrate will be Described in Peer Reviewed Paper Phoenix, AZ September 4, 2019 Creative Medical Technology Holdings (OTC-CELZ)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commissio

JLLM / Jolley Marketing, Inc. PRE 14C - - PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) ¨ Definitive Information Statement CREATIVE MEDICAL TE

JLLM / Jolley Marketing, Inc. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE

Securities Purchase Agreement, dated as of July 29, 2019, between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 29, 2019, among Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, the parties hereto d

Form of 8% Original Issue Discount Senior Convertible Note issued under Securities Purchase Agreement dated as of July 29, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of July 29, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.2 EITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commission Fi

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of June 28, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.2 EITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA

Form of 8% Original Issue Discount Senior Convertible Note issued under Securities Purchase Agreement dated as of June 28, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commission Fil

Securities Purchase Agreement, dated as of June 28, 2018, between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2019, among Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, the parties hereto d

JLLM / Jolley Marketing, Inc. 10-K/A - Annual Report - FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500

100+ Patients Treated for Erectile Dysfunction Utilizing Company’s Patented CaverStem® Stem Cell Procedure with Significant Success Rate General corporate updates and plans for second half of 2019.

Exhibit 99.1 100+ Patients Treated for Erectile Dysfunction Utilizing Company’s Patented CaverStem® Stem Cell Procedure with Significant Success Rate General corporate updates and plans for second half of 2019. Phoenix, AZ, June 20, 2019 – Creative Medical Technology Holdings, Inc. (OTCQB: CELZ), a leading commercial stage biotechnology company focused on Urology, Orthopedics and Neurology using s

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commission Fi

JLLM / Jolley Marketing, Inc. 10-K/A - Annual Report - 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500

JLLM / Jolley Marketing, Inc. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 Creative

JLLM / Jolley Marketing, Inc. NT 10-Q NT 10-Q

NT 10-Q 1 tv521760nt10q.htm NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 Commission File Number 000-53500 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: March 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Creative Medical Technology Holdings, Inc. April 2019 Shareholder Update

Exhibit 99.1 Creative Medical Technology Holdings, Inc. April 2019 Shareholder Update 9:15 AM ET 4/30/19 | PR Newswire PHOENIX, April 30, 2019 /PRNewswire/ - (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: As we are releasing updates on a regular basis, we will only cover new activities. The absence of reporting on a specific area of our busines

CaverStem Stem Cell Treatment Of Erectile Dysfunction Receives Additional International Exposure

Exhibit 99.2 CaverStem Stem Cell Treatment Of Erectile Dysfunction Receives Additional International Exposure 7:45 AM ET 5/6/19 | PR Newswire PHOENIX and ROME, May 6, 2019 /PRNewswire/ - Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today coverage of its patented CaverStem(R) technology for treatment of erectile dysfunction using the patient's own non-manipulated and non-expand

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorporat

Creative Medical Technology Holdings, Inc. March 28, 2019 Shareholder Update

Exhibit 99.1 Creative Medical Technology Holdings, Inc. March 28, 2019 Shareholder Update PR NewswireMarch 28, 2019 PHOENIX, March 28, 2019 /PRNewswire/ - (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: CaverStem™ domestic activities: As previously reported, we are continuing marketing to physicians across the United States. Since our last share

Articles of Incorporation

Exhibit 3.1 ARTICLES OF INCORPORATION (As Filed on 12/3/1998, As Amended on 9/05/2007, 7/16/2008, 7/11/2011, 5/18/2016, & 2/13/18) Creative Medical Technology Holdings, Inc. ARTICLE I (As amended 5/18/2016) The name of the corporation (which is hereinafter referred to as the "Corporation") is Creative Medical Technology Holdings, Inc. ARTICLE II The address of the registered office of the Corporat

Code of Business Conduct and Ethics

Exhibit 10.28 Creative Medical Technology Holdings, Inc. CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction This Code of Business Conduct and Ethics (this “Code”) has been adopted by our board of directors (the “Board of Directors”) to summarize the standards of business conduct that must guide our actions. This Code applies to all directors, officers, and employees of Creative Medical Technology

JLLM / Jolley Marketing, Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 CREATIVE MEDICAL

Securities Purchase Agreement, dated as of February 19, 2018, between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2019, between Creative Medical Technology Holdings, Inc., a Nevada corporation and its predecessors (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purcha

Form of Promissory Note issued under Exchange Agreements dated as of February 28, 2019 between Creative Medical Technology Holdings, Inc. and the warrant holders named therein

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of February 19, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Promissory Note issued under Securities Purchase Agreement dated as of February 19, 2019 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Exchange Agreement, dated as of February 28, 2019, between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 10.1 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (the “Agreement”) is made as of the 28th day of February 2019, by and between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and , a company (the “Investor”). WHEREAS, on September 20, 2018 the Company executed and delivered to the Investor a Common Stock Purchase Warrant in respect of 1,247,618 shares of co

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commissio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2019 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

SHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Exhibit 99.1 SHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Phoenix, AZ 2-12-19, (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of it’s activities: This update addresses the goals set for Q1 2019 with regard to the ongoing commercialization of the CaverStemTM and FemCelzTM components of our company.. We are reaching those goals. We are continuing

Creative Medical Technology Holdings, Inc. December 2018 Shareholder Update

Exhibit 99.1 Creative Medical Technology Holdings, Inc. December 2018 Shareholder Update PHOENIX, Dec. 27, 2018 /PRNewswire/ - (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: As we end 2018 we look forward to continuing to reach multiple milestones in 2019. CaverStem™ domestic activities: As previously reported, we are continuing marketing to ph

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2018 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpo

Securities Purchase Agreement, dated as of November 15, 2018, between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 15, 2018, between Creative Medical Technology Holdings, Inc., a Nevada corporation and its predecessors (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purcha

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2018 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commissio

Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of November 15, 2018 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Promissory Note issued under Securities Purchase Agreement dated as of November 15, 2018 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

JLLM / Jolley Marketing, Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53500 Crea

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpor

Creative Medical Technology Holdings, Inc. Announces New Design To Caverstem Website Including New Features For Physician/Patient Engagement

Exhibit 99.1 Creative Medical Technology Holdings, Inc. Announces New Design To Caverstem Website Including New Features For Physician/Patient Engagement PHOENIX, Nov. 6, 2018 /PRNewswire/ - Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that as a continuation of the Brand Building of its CaverStemTM technology, it has awarded a contract to PatientGain Medica

Shareholder Update: Creative Medical Technology Holdings, Inc.

Exhibit 99.1 Shareholder Update: Creative Medical Technology Holdings, Inc. PHOENIX, Oct. 17, 2018 /PRNewswire/ - (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: Creative Medical Health, Inc. shall convert $100,000.00 of deferred management compensation to CELZ stock at a VWAP of $0.0225 per share, which will result in 4,444,444 shares of CELZ s

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2018 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 87-0622284 (State or other jurisdiction of incorpor

JLLM / Jolley Marketing, Inc. / Warbington Timothy - AMENDMENT NO. 4 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4) Creative Medical Technology Holdings, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 22529Y 101 (CUSIP Number) Timothy Warbington 2017 W Peoria Avenue Phoenix, AZ 85029 (833) 336-7636 (Name, Address and Tel

Form of Common Stock Purchase Warrant, dated September 20, 2018, issued under Securities Purchase Agreement dated as of September 13, 2018 between Creative Medical Technology Holdings, Inc. and the investors named therein

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2018 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-53500 88-0622284 (State or other jurisdiction (Commissi